Research has found that the SIRT2/ERK/c-MYC axis plays a crucial role in promoting liver fibrosis, and SIRT2 inhibitors are a potential new strategy for treating liver fibrosis and cirrhosis. Here, MYC is linked to Hepatic fibrosis.